- Trials with a EudraCT protocol (123)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
123 result(s) found for: Ethyl.
Displaying page 4 of 7.
EudraCT Number: 2006-002207-13 | Sponsor Protocol Number: NRA1280023 | Start Date*: 2006-06-29 |
Sponsor Name:Dept. Child & Adolescent Psychiatry Univ. Freiburg | ||
Full Title: Ziprasidone for severe conduct and other disruptive behavior disorders in children and adolescents – a placebo controlled, randomized, double blind clinical trial | ||
Medical condition: conduct disorder (CD), oppositional defiant disorder (ODD) and disruptive behavior disorder not otherwise specified (DBD-NOS) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-005501-28 | Sponsor Protocol Number: A1281134 | Start Date*: 2006-05-04 | |||||||||||
Sponsor Name:Pfizer AB | |||||||||||||
Full Title: Six week, double-blind, placebo controlled Phase III trial evaluating the efficacy, safety and pharmacokinetics of flexible doses of oral ziprasidone in adolescent subjects with schizophrenia. | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003777-28 | Sponsor Protocol Number: OBADIAH1 | Start Date*: 2012-04-26 |
Sponsor Name:Imperial College London and Imperial College Healthcare NHS Trust | ||
Full Title: Obeticholic acid treatment in patients with bile acid diarrhoea: an open-label, pilot study of mechanisms, safety and symptom response. | ||
Medical condition: Bile acid diarrhoea (also known as bile acid malabsorption) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-004750-24 | Sponsor Protocol Number: 2013003 | Start Date*: 2014-03-17 | |||||||||||
Sponsor Name:Rode Kruis Ziekenhuis | |||||||||||||
Full Title: Omega-3 fatty acids in bariatric gastric bypass surgery: effects on liver volume, immune response and erythrocyte function | |||||||||||||
Medical condition: Patients qualified for bariatric surgery | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005571-14 | Sponsor Protocol Number: TIMING | Start Date*: 2013-08-02 |
Sponsor Name:INSTITUTO DE INVESTIGACION SANITARIA LA FE | ||
Full Title: CLINICAL TRIAL, SINGLE BLIND, RANDOMIZED, CONTROLLED PROSPECTIVE EVALUATION FOR OPTIMUM TIME INTERVAL BETWEEN ACETATE ADMINISTRATION AND PUNCTURE TRIPTORELIN FOLLICULAR IN IVF TREATMENT | ||
Medical condition: INFERTILITY | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-002430-34 | Sponsor Protocol Number: H9U-MC-MDBE | Start Date*: 2005-10-25 |
Sponsor Name:Eli Lilly & Company Limited | ||
Full Title: Effects of 5HT2A Blockade in Depressed Patients with Inadequate Antidepressant Treatment Response | ||
Medical condition: The aim of the study is to test augmentation of SSRI therapy with LY2422347 in patients who continue to manifest significant levels of depressive symptoms following an adequate treatment with an SS... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: HU (Completed) ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-000819-25 | Sponsor Protocol Number: DS102A-05-AH1 | Start Date*: 2019-01-31 | |||||||||||
Sponsor Name:Afimmune | |||||||||||||
Full Title: A Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Orally Administered DS102 in Patients with Severe Acute Decompensated Alcoholic Hepatitis. | |||||||||||||
Medical condition: Severe Acute Decompensated Alcoholic Hepatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) LV (Prematurely Ended) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004210-28 | Sponsor Protocol Number: I-1315 | Start Date*: 2015-01-29 | |||||||||||||||||||||
Sponsor Name:Department of Nuclear Medicine, Aalborg University Hospital | |||||||||||||||||||||||
Full Title: 68Ga-PSMA PET/CT vs. MRI/CT vs. lymphadenectomy for the identification of lymph node metastases in locally advanced prostate cancer patients: a diagnostic test accuracy study | |||||||||||||||||||||||
Medical condition: Patients diagnosed with advanced prostate cancer that are scheduled for lymph node staging. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||||||||||||
Trial protocol: DK (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-021220-10 | Sponsor Protocol Number: D2610C00003 | Start Date*: 2010-10-07 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Randomised Double-blind Phase IIa Study (with Combination Safety Run-in) to Assess the Safety and Efficacy of AZD4547 in Combination with Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Pa... | |||||||||||||
Medical condition: ER+ Breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) FR (Completed) DE (Completed) HU (Completed) CZ (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005073-37 | Sponsor Protocol Number: I-1409 | Start Date*: 2015-02-02 | ||||||||||||||||||||||||||
Sponsor Name:Department of Nuclear Medicine, Aalborg University Hospital | ||||||||||||||||||||||||||||
Full Title: 68Ga-PSMA PET/CT for detection of recurrent prostate cancer: Comparison with 18F-fluoride PET/CT, MRI and DW-MRI | ||||||||||||||||||||||||||||
Medical condition: Patients diagnosed with biochemical (PSA) relapse following curative intended treatment (defined as radical prostatectomy or radiotherapy, either by external beam radiotherapy or low- or high-dose ... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | |||||||||||||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-003822-25 | Sponsor Protocol Number: EORTC 08051 | Start Date*: 2006-06-19 | |||||||||||
Sponsor Name:European Organisation for Research and Treatment of Cancer | |||||||||||||
Full Title: Randomized Phase II Study Of Pemetrexed And Cisplatin As Either Induction or Adjuvant Chemotherapy In Stage IB-II Non-Small Cell Lung Cancer (NSCLC) | |||||||||||||
Medical condition: Stage IB-II Non-Small Cell Lung Cancer (NSCLC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005969-13 | Sponsor Protocol Number: AXA1665-101 | Start Date*: 2021-08-11 | ||||||||||||||||
Sponsor Name:Axcella Health, Inc. | ||||||||||||||||||
Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of AXA1665 in Subjects With Liver Cirrhosis and Prior Overt Hepatic Encephalopathy (EM... | ||||||||||||||||||
Medical condition: Overt Hepatic Encephalopathy in Subjects with Liver Cirrhosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Completed) PL (Completed) HU (Prematurely Ended) IT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000780-48 | Sponsor Protocol Number: J3E-MC-EZDB | Start Date*: 2022-11-28 | ||||||||||||||||
Sponsor Name:Eli Lilly and Company | ||||||||||||||||||
Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3540378 in Adults with Worsening Chronic Heart Failure with Preserved Ejection Fraction (HF... | ||||||||||||||||||
Medical condition: HFpEF (heart failure with preserved ejection fraction) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Trial now transitioned) ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-000465-37 | Sponsor Protocol Number: 0524A-082 | Start Date*: 2008-05-30 | |||||||||||
Sponsor Name:Laboratoires Merck Sharp & Dohme - Chibret | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Ther... | |||||||||||||
Medical condition: Dyslipidemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) AT (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000872-40 | Sponsor Protocol Number: CLCQ908C2201 | Start Date*: 2012-11-13 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A pilot study to assess the efficacy and safety of LCQ908 alone and in combination with fenofibrate or Lovaza® in patients with severe hypertriglyceridemia | |||||||||||||
Medical condition: Non Familial Chylomicronemia Syndrome (Non-FCS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003596-36 | Sponsor Protocol Number: RAPID-1DFU[2018/08] | Start Date*: 2018-11-30 | |||||||||||
Sponsor Name:Biotherapy Services Ltd. | |||||||||||||
Full Title: A single centre, open label Randomised Controlled Trial of the RAPID™* PRP (Platelet Rich Plasma) Haematogel Wound Care Treatment in addition to Usual and Customary Care, (UCC); compared to Usual a... | |||||||||||||
Medical condition: The treatment of chronic diabetic foot ulcers of longer than 12weeks duration. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000736-33 | Sponsor Protocol Number: CAFQ056X2201 | Start Date*: 2017-10-25 | |||||||||||
Sponsor Name:Novartis Farmacéutica S.A. | |||||||||||||
Full Title: A randomized, subject and investigator blinded, placebo-controlled, parallel group study to investigate whether AFQ056 reduces cocaine use in patients diagnosed with Cocaine Use Disorder (CUD). | |||||||||||||
Medical condition: Cocaine Use Disorder according to DSM 5 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001477-14 | Sponsor Protocol Number: HCC-P3-11-01 | Start Date*: 2012-06-15 | |||||||||||
Sponsor Name:MERIT MEDICAL SYSTEMS, INC. | |||||||||||||
Full Title: Phase 3 Prospective,Randomized, blinded and controlled investigation of Hepasphere/Quadrasphere microspheres for delivery of doxorubicin for the treatment of hepatocellular cancer. This Study is Ph... | |||||||||||||
Medical condition: Liver Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-005532-32 | Sponsor Protocol Number: KWI-NIC-02 | Start Date*: 2009-03-13 | |||||||||||
Sponsor Name:Kwizda Pharma | |||||||||||||
Full Title: The bioavailability of nicorandil in humans: A pilot study to investigate the variability of its pharmacokinetic parameters in healthy volunteers. | |||||||||||||
Medical condition: The bioavailability of Nicorandil in humans: A pilot study to investigate the variability of the pharmacokinetic parameters in healthy volunteers. The IMP Nicorandil (2-(pyridine-3-carbonylamino)et... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001500-13 | Sponsor Protocol Number: A0081012 | Start Date*: 2005-01-24 | |||||||||||
Sponsor Name:Pfizer Ltd. | |||||||||||||
Full Title: An 8-week, multicentre, randomised, double-blind, placebo-controlled, flexible dose study of Pregabalin (300-600 mg/day) and Venlafaxine XR (75-225 mg/day) for the acute treatment of DSM-IV General... | |||||||||||||
Medical condition: Generalized Anxiety Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) SE (Completed) GB (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
